Financial reports
10-Q
2023 Q3
Quarterly report
14 Feb 23
10-Q
2023 Q2
Quarterly report
10 Nov 22
10-Q
2023 Q1
Quarterly report
11 Aug 22
10-K
2022 FY
Annual report
14 Jun 22
10-Q
2022 Q3
Quarterly report
11 Feb 22
10-Q
2022 Q2
Quarterly report
12 Nov 21
10-Q
2022 Q1
Quarterly report
12 Aug 21
10-K
2021 FY
Annual report
9 Jun 21
10-Q
2021 Q3
Quarterly report
9 Feb 21
10-Q
2021 Q2
Quarterly report
13 Nov 20
Current reports
8-K
Departure of Directors or Certain Officers
6 Apr 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
15 Mar 23
8-K
Sio Gene Therapies Announces Fiscal Third Quarter 2022 Financial Results
14 Feb 23
8-K
Sio Gene Therapies Inc. Announces Board Approval of Plan of Complete Liquidation and Dissolution
14 Dec 22
8-K
Sio Gene Therapies Announces Fiscal Second Quarter 2022 Financial Results
10 Nov 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
14 Sep 22
8-K
Sio Gene Therapies Announces Fiscal First Quarter 2022 Financial Results
11 Aug 22
8-K
Sio Gene Therapies Announces Fiscal Year 2021 Year-End Financial Results
14 Jun 22
8-K
Sio Gene Therapies Provides Corporate Update
27 Apr 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
18 Mar 22
Registration and prospectus
15-12G
Securities registration termination
25 Apr 23
POS AM
Prospectus update (post-effective amendment)
17 Apr 23
S-8 POS
Registration of securities for employees (post-effective amendment)
17 Apr 23
25-NSE
Exchange delisting
12 Apr 23
25
Voluntary exchange delisting
6 Apr 23
S-8
Registration of securities for employees
6 Oct 21
424B5
Prospectus supplement for primary offering
16 Dec 20
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Nov 20
POS AM
Prospectus update (post-effective amendment)
13 Nov 20
POS AM
Prospectus update (post-effective amendment)
13 Nov 20
Proxies
DEFA14A
Additional proxy soliciting materials
16 Mar 23
DEFM14A
Proxy related to merger
21 Feb 23
DEFA14A
Additional proxy soliciting materials
14 Feb 23
PREM14A
Preliminary proxy related to merger
8 Feb 23
DEFA14A
Additional proxy soliciting materials
14 Dec 22
DEFA14A
Additional proxy soliciting materials
6 Aug 21
DEF 14A
Definitive proxy
6 Aug 21
DEFA14A
Additional proxy soliciting materials
12 Aug 20
DEF 14A
Definitive proxy
12 Aug 20
DEF 14C
Information statement
2 Mar 20
Other
EFFECT
Notice of effectiveness
25 Apr 23
EFFECT
Notice of effectiveness
20 Nov 20
EFFECT
Notice of effectiveness
20 Nov 20
EFFECT
Notice of effectiveness
13 Nov 20
CORRESP
Correspondence with SEC
10 Nov 20
UPLOAD
Letter from SEC
8 Oct 20
EFFECT
Notice of effectiveness
16 Jun 20
CORRESP
Correspondence with SEC
11 Jun 20
UPLOAD
Letter from SEC
16 Jan 20
CT ORDER
Confidential treatment order
6 Mar 19
Ownership
SC 13G/A
SUVRETTA CAPITAL MANAGEMENT, LLC
13 Feb 23
SC 13G
Rubric Capital Management LP
10 Feb 23
SC 13G/A
Consonance Capital Management LP
14 Feb 22
SC 13G/A
SUVRETTA CAPITAL MANAGEMENT, LLC
11 Feb 22
4
Parag V Meswani
10 Feb 22
4
David W. Nassif
10 Feb 22
3
Parag V Meswani
7 Feb 22
4
David W. Nassif
9 Dec 21
4
Pavan Cheruvu
9 Dec 21
4
Kristiina MD Vuori
19 Apr 21